1
Clinical Trials associated with Apomivir(Far East Bio-Tec) / Not yet recruitingPhase 2 A Prospective, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Apomivir® in Relieving Influenza Symptoms
Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.
100 Clinical Results associated with Apomivir(Far East Bio-Tec)
100 Translational Medicine associated with Apomivir(Far East Bio-Tec)
100 Patents (Medical) associated with Apomivir(Far East Bio-Tec)
100 Deals associated with Apomivir(Far East Bio-Tec)